Xochiquetzal U Martinez1, Arnab Chowdhury2, Tracey Stiller2, Joycelynne Palmer2, Matthew Loscalzo3, Estella Barrios3, Farah R Abdulla1, Jasmine Zain4, Steven T Rosen4,5, Christiane Querfeld6,7. 1. Division of Dermatology, City of Hope, Duarte, USA. 2. Division of Biostatistics, City of Hope, Duarte, USA. 3. Patient & Family Resource Center, City of Hope, Duarte, USA. 4. Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, USA. 5. Beckman Research Institute, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA. 6. Division of Dermatology, City of Hope, Duarte, USA. cquerfeld@coh.org. 7. Beckman Research Institute, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA. cquerfeld@coh.org.
Abstract
PURPOSE: Cutaneous lymphomas (CLs) are a group of rare, potentially disfiguring and disabling cancers that can have a significant impact on quality of life (QoL). While previous studies have shown that mycosis fungoides (MF) and Sézary syndrome (SS) impair QoL, the effect of other types of CL on QoL has not been evaluated. OBJECTIVE: To determine the impact of disease on QoL in all CL patients and to assess how QoL between the CL sub-types varies by demographic and clinical factors. METHODS: The Cutaneous Lymphoma Distress Questionnaire (CL-DQ) was used to assess QoL. All CL patients seen in a multidisciplinary CL clinic were screened for eligibility. Questionnaire responses were collected over a 22-month period between 2017 and 2019. A cross-sectional analysis of CL-DQ scores from an initial visit was performed to determine the effect of disease on QoL across CL sub-types and the potential impact of patient demographics, CL sub-type, and type of treatment. RESULTS: The study population consisted of 151 patients presenting with distinct types of cutaneous B- and T-cell lymphomas. Notable across the study population were the findings of frustration (44%), worry about progress/spread (43%), itching/pruritus (32%), and embarrassment/shame (28%). QoL was found to be most negatively affected in SS patients, females, younger patients, Black patients, and those with advanced stages of MF/SS. CONCLUSIONS: Impairment of QoL due to CL correlates with gender, age, race/ethnicity, and stage of MF/SS. While the negative impact on QoL is most pronounced in SS patients, other CL sub-types also affect QoL and impact psychosocial distress. Our findings highlight the need for QoL assessment in all CL patients and further examination of disparities noted across demographic groups.
PURPOSE: Cutaneous lymphomas (CLs) are a group of rare, potentially disfiguring and disabling cancers that can have a significant impact on quality of life (QoL). While previous studies have shown that mycosis fungoides (MF) and Sézary syndrome (SS) impair QoL, the effect of other types of CL on QoL has not been evaluated. OBJECTIVE: To determine the impact of disease on QoL in all CL patients and to assess how QoL between the CL sub-types varies by demographic and clinical factors. METHODS: The Cutaneous Lymphoma Distress Questionnaire (CL-DQ) was used to assess QoL. All CL patients seen in a multidisciplinary CL clinic were screened for eligibility. Questionnaire responses were collected over a 22-month period between 2017 and 2019. A cross-sectional analysis of CL-DQ scores from an initial visit was performed to determine the effect of disease on QoL across CL sub-types and the potential impact of patient demographics, CL sub-type, and type of treatment. RESULTS: The study population consisted of 151 patients presenting with distinct types of cutaneous B- and T-cell lymphomas. Notable across the study population were the findings of frustration (44%), worry about progress/spread (43%), itching/pruritus (32%), and embarrassment/shame (28%). QoL was found to be most negatively affected in SS patients, females, younger patients, Black patients, and those with advanced stages of MF/SS. CONCLUSIONS: Impairment of QoL due to CL correlates with gender, age, race/ethnicity, and stage of MF/SS. While the negative impact on QoL is most pronounced in SS patients, other CL sub-types also affect QoL and impact psychosocial distress. Our findings highlight the need for QoL assessment in all CL patients and further examination of disparities noted across demographic groups.
Authors: Heather M Holahan; Ronda S Farah; Sara Fitz; Sarah L Mott; Nkanyezi N Ferguson; Julie McKillip; Brian Link; Vincent Liu Journal: Int J Dermatol Date: 2018-08-03 Impact factor: 2.736
Authors: Cleo A Samuel; Laura C Pinheiro; Katherine E Reeder-Hayes; Jennifer S Walker; Giselle Corbie-Smith; Shekinah A Fashaw; Cheryl Woods-Giscombe; Stephanie B Wheeler Journal: Breast Cancer Res Treat Date: 2016-09-06 Impact factor: 4.872
Authors: F Sampogna; M Frontani; G Baliva; G A Lombardo; G Alvetreti; C Di Pietro; S Tabolli; G Russo; D Abeni Journal: Br J Dermatol Date: 2008-12-16 Impact factor: 9.302
Authors: Shamir Geller; Emily Lebowitz; Melissa P Pulitzer; Steven M Horwitz; Alison J Moskowitz; Steve Dusza; Patricia L Myskowski Journal: J Am Acad Dermatol Date: 2019-09-06 Impact factor: 11.527
Authors: Jennifer A Salant; Niloufer Khan; Judith E Nelson; Moe Norton-Westbrook; Anjali V Desai Journal: J Palliat Med Date: 2021-12-31 Impact factor: 2.947